Drug Trial Radar · NCT07079631
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
482
Planned (sponsor's estimate)
Start
Jul 18, 2025
Primary completion
Dec 2030
Study completion Dec 2032
Sponsor
- Lead sponsor
- BioNTech SEIndustry
- Sponsor type
- Industry
- Collaborators
- Genmab
- First posted
- Jul 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized, multi-site, three-part study will test a new treatment called BNT314, which is designed to help the body's own defense to fight cancer in combination with another new treatment (pumitamig, which is a cancer immunotherapy drug also known as BNT327 and PM8002) and chemotherapy in participants with metastatic colorectal cancer (mCRC).
Conditions
- Metastatic Colorectal Cancer
Interventions
BNT314Biological
Intravenous (IV) infusion
PumitamigDrug
IV infusion
SoC chemotherapy treatment 1Drug
IV infusion / IV bolus
SoC chemotherapy treatment 2Drug
IV infusion / IV bolus / oral
BevacizumabDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I - Part A: Occurrence of dose limiting toxicities (DLTs) during the DLT observation periodTime frame: Up to 28 days after Day 1, Cycle 1
- Phase I - Part A: Occurrence of treatment emergent adverse events (TEAEs) and treatment related adverse events (TRAEs)Time frame: From initiation of the first dose of BNT314 + pumitamig until 90 days after last dose of investigational medicinal product (IMP)
- Phase I - Part A: Occurrence of dose interruption or discontinuation of study treatment due to TEAEsTime frame: From initiation of the first dose of BNT314 + pumitamig until 90 days after last dose of IMP
- Phase I - Part B: Occurrence DLTs during the DLT observation period for the first five participants in each dose cohortTime frame: Up to 42 days after Day 1, Cycle 1
- Phase I - Part B: Occurrence of TEAEs and TRAEsTime frame: From initiation of the first dose of BNT314 + pumitamig + SoC chemotherapy until 90 days after last dose of IMP
- Phase I - Part B: Occurrence of dose interruption or discontinuation of study treatment due to TEAEsTime frame: From initiation of the first dose of BNT314 + pumitamig + SoC chemotherapy until 90 days after last dose of IMP
- Phase I - Part B: Objective response rate (ORR)Time frame: From the time of initiation of the first dose of IMP to end of study, up to 57 months
- Phase II - Part C: Progression free survivalTime frame: From the time of initiation of the first dose of IMP to end of study, up to 57 months
Locations
14 sites in 5 countries. Site status is shown where the registry gives one.
Yale University
New Haven, Connecticut · Recruiting
START Midwest
Grand Rapids, Michigan · Recruiting
Cleveland Clinic Taussig Cancer Institute Case Comprehensive Cancer Center
Cleveland, Ohio · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Hämatologisch-Onkologische Praxis Eppendorf - HOPE
Hamburg, Germany · Recruiting
Asklepios Tumorzentrum Hamburg
Hamburg, Germany · Recruiting
National Cancer Center Hospital
Chūōku, Japan · Recruiting
National Cancer Center Hospital East
Kashiwa, Japan · Recruiting
Hospital HM Nou Delfos
Barcelona, Spain · Recruiting
Vall D'Hebrón Hospital
Barcelona, Spain · Recruiting
Centro Integral Oncologico Clara Campal
Madrid, Spain · Recruiting
Guy's & St Thomas' NHS Foundation Trust, Guy's Hospital
London, United Kingdom · Recruiting
Christie NHS Foundation
Manchester, United Kingdom · Recruiting
The Royal Marsden NHS
Sutton, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.